News

Enlarge image

ResearchDenmarkSwitzerland

Antibody mends a broken heart

11.03.2013 - Genmab's antibody drug inclacumab significantly reduces damage to the heart muscle during angioplasty, Canadian researchers reported at the ACC Meeting.

In patients with acute coronary syndrome (ACS), who were treated by opening the blocked artery (Angioplasty/Percutaneous Coronary Intervention, PCI), Inclacumab (RO4905417, RG1512) helped significantly to lower the levels of  a biomarker clinically used to diagnose heart attacks. A single shot of the human anti-inflammatory antibody, which is co-developed by Genmab and Roche, reduced Troponin I levels by 24%, said Principal Investigator Dr. Jean-Claude Tardif from University of Montreal at the  international meeting of the American College of Cardiology (ACC) on 10 March.

"Inclacumab could indeed become an integral part of the therapeutic arsenal of modern cardiology if we can reproduce these results in subsequent studies", said the Director of the Research Centre at the Montreal Heart Institute. "We could use the drug for a broader patient population, or for all patients who present with a heart attack, but this will require further study." The human antibody targets P-selectin, a molecule which plays an important role in sending white blood cells to the site of an injury during inflammation.  

The Phase II trial conducted by Roche involved 530 patients with myocardial infarction who were randomised to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg, or placebo 1 to 24 hours before angioplasty. Markers for heart damage were then measured at 8, 16 and 24 hours after angioplasty.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/antibody-mends-a-broken-heart.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR109.4%
  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-39.1%
  • PLETHORA (UK)2.75 GBP-33.3%
  • BIONOR PHARMA (N)0.88 NOK-30.2%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 06.02.2016